On May 18, 2022, Prescience Point Capital Management LLC issued a statement expressed its sisappoint that the MiMedx Board has resorted to disinformation and distortions to distract shareholders from the board's and management's own failures. Prescience Point reiterates its intention to withhold votes against directors Phyllis Gardner and James Bierman at 2022 annual meeting and vote against approval of executive compensation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.43 USD | -1.23% | +1.58% | -26.68% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.68% | 961M | |
-18.52% | 131M | |
+7.32% | 63.05M | |
-15.34% | 61.84M | |
+1.20% | 50.36M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- Prescience Point Capital Management Provides Information to the Shareholders